Topics

FDA Grants Niraparib Breakthrough Designation for BRCA+ mCRPC

18:45 EDT 3 Oct 2019 | OncLive

The FDA has granted a breakthrough therapy designation to the PARP inhibitor niraparib for the treatment of patients with BRCA1/2–mutant metastatic castration-resistant prostate cancer who have previously received chemotherapy and an androgen receptor inhibitor.

Original Article: FDA Grants Niraparib Breakthrough Designation for BRCA+ mCRPC

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Niraparib Breakthrough Designation for BRCA+ mCRPC"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...